High Dose Vitamin D Cancer

Randomized Controlled Trial

. 2018 Nov 1;4(11):e182178.

doi: 10.1001/jamaoncol.2018.2178. Epub 2018 Nov 8.

Monthly High-Dose Vitamin D Supplementation and Cancer Risk: A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial

Affiliations

PMID: 30027269
PMCID: PMC6248079
DOI: 10.1001/jamaoncol.2018.2178

Free PMC article

Randomized Controlled Trial

Monthly High-Dose Vitamin D Supplementation and Cancer Risk: A Post Hoc Analysis of the Vitamin D Assessment Randomized Clinical Trial

Robert Scragg et al. JAMA Oncol. 2018 .

Free PMC article

Abstract

Importance: Previous randomized clinical trials have reported inconsistent results on the effect of vitamin D supplementation on cancer incidence.

Objective: To examine whether high-dose vitamin D supplementation received monthly, without calcium, is associated with a reduction in cancer incidence and cancer mortality in the general population.

Design, setting, and participants: This is a post hoc analysis of data from the Vitamin D Assessment (ViDA) study, a randomized, double-blind, placebo-controlled trial that recruited participants from family practices and community groups in Auckland, New Zealand, from April 5, 2011, through November 6, 2012, with follow-up completed December 31, 2015. Participants were adult community residents aged 50 to 84 years. Of 47 905 adults invited from family practices and 163 from community groups, 5110 participants were randomized to receive vitamin D3 (n = 2558) or placebo (n = 2552). Two participants withdrew consent, and all others (n = 5108) were included in the primary analysis. Data analysis was by intention to treat.

Interventions: Oral vitamin D3, in an initial bolus dose of 200 000 IU and followed by monthly doses of 100 000 IU, or placebo for a median of 3.3 years (range, 2.5-4.2 years).

Main outcomes and measures: Post hoc primary outcome was the number of all primary invasive and in situ malignant neoplasms (excluding nonmelanoma skin cancers) diagnosed from randomization until the study medication was discontinued on July 31, 2015.

Results: Of the 5108 participants included in the analysis, the mean (SD) age was 65.9 (8.3) years, 58.1% were male, and 4253 (83.3%) were of European or another race/ethnicity, with the remainder being Polynesian or South Asian. Mean (SD) baseline deseasonalized 25-hydroxyvitamin D concentration was 26.5 (9.0) ng/mL. In a random sample of 438 participants, the mean follow-up 25-hydroxyvitamin D concentration consistently was greater than 20 ng/mL higher in the vitamin D group than in the placebo group. The primary outcome of cancer comprised 328 total cases of cancer (259 invasive and 69 in situ malignant neoplasms) and occurred in 165 of 2558 participants (6.5%) in the vitamin D group and 163 of 2550 (6.4%) in the placebo group, yielding an adjusted hazard ratio of 1.01 (95% CI, 0.81-1.25; P = .95).

Conclusions and relevance: High-dose vitamin D supplementation prescribed monthly for up to 4 years without calcium may not prevent cancer. This study suggests that daily or weekly dosing for a longer period may require further study.

Trial registration: anzctr.org.au Identifier: ACTRN12611000402943.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

**Figure 1.. Flow Diagram in the Vitamin D Assessment Study for Cancer Outcome**

**Figure 2.. Proportion of Participants Developing Cancer During Follow-up From June 3, 2011, to July 31, 2015, by Study Group**
Shaded areas represent 95% CIs for the 2 curves.

Cited by 38 articles

Potential of Vitamin D Food Fortification in Prevention of Cancer Deaths-A Modeling Study.

Niedermaier T, Gredner T, Kuznia S, Schöttker B, Mons U, Brenner H. Niedermaier T, et al. Nutrients. 2021 Nov 9;13(11):3986. doi: 10.3390/nu13113986. Nutrients. 2021. PMID: 34836241 Free PMC article.
The health effects of vitamin D supplementation: evidence from human studies.

Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, Richards JB. Bouillon R, et al. Nat Rev Endocrinol. 2021 Nov 23:1-15. doi: 10.1038/s41574-021-00593-z. Online ahead of print. Nat Rev Endocrinol. 2021. PMID: 34815552 Free PMC article. Review.
Vitamin D Supplementation and Cancer Mortality: Narrative Review of Observational Studies and Clinical Trials.

Gnagnarella P, Muzio V, Caini S, Raimondi S, Martinoli C, Chiocca S, Miccolo C, Bossi P, Cortinovis D, Chiaradonna F, Palorini R, Facciotti F, Bellerba F, Canova S, Gandini S. Gnagnarella P, et al. Nutrients. 2021 Sep 21;13(9):3285. doi: 10.3390/nu13093285. Nutrients. 2021. PMID: 34579164 Free PMC article. Review.
Biochemical characteristics and calcium and PTH levels of patients with high normal and elevated serum 25(OH)D levels in Turkey: DeVIT-TOX survey.

Pekkolay Z, Yavuz DG, Saygılı ES, Değertekin CK, Topaloğlu Ö, Önder ÇE, Soylu H, Taskaldıran I, Pazır AE, Uğur K, Tanrıkulu S, Fırat SN, Atak BM, Batman A, Omma T, Cağıltay E, Özdemir N, Altuntaş SÇ, İmga NN, Karakılıç E, Hekimsoy Z, Kılınç F, Yay A, Eroğlu M, Tuzcu AK. Pekkolay Z, et al. Arch Osteoporos. 2021 Sep 18;16(1):138. doi: 10.1007/s11657-021-01002-8. Arch Osteoporos. 2021. PMID: 34536116
Vitamin D supplementation for chronic liver diseases in adults.

Bjelakovic M, Nikolova D, Bjelakovic G, Gluud C. Bjelakovic M, et al. Cochrane Database Syst Rev. 2021 Aug 25;8(8):CD011564. doi: 10.1002/14651858.CD011564.pub3. Cochrane Database Syst Rev. 2021. PMID: 34431511 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- Ovid Technologies, Inc.
- PubMed Central
- Silverchair Information Systems
Other Literature Sources
- Faculty Opinions
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

High Dose Vitamin D Cancer

Source: https://pubmed.ncbi.nlm.nih.gov/30027269/

Xiomara Top Form

High Dose Vitamin D Cancer